MGMT and glioblastoma: In addition, in our cohort, poor prognostic patients with GBM, unmethylated MGMT status, treated with BEV + TMZ showed improved OS (TMZ + BEV vs. TMZ median OS: 16.7 vs. 12.2 months, p = 0.04) [29].